NCT06195306View on ClinicalTrials.gov

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

PHASE2RecruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

October 1, 2027

Study Completion Date

January 1, 2028

Conditions
Breast Atypical HyperplasiaBreast CarcinomaBreast Ductal Carcinoma In SituBreast Lobular Carcinoma In Situ
Interventions
PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

PROCEDURE

Mammography

Undergo mammography

DRUG

Omega-3-Acid Ethyl Esters

Given PO

OTHER

Questionnaire Administration

Ancillary studies

PROCEDURE

Random Periareolar Fine-Needle Aspiration

Undergo RPFNA

DRUG

Tamoxifen

Given PO

Trial Locations (3)

43210

NOT_YET_RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus

48109

RECRUITING

University of Michigan Comprehensive Cancer Center, Ann Arbor

66160

NOT_YET_RECRUITING

University of Kansas Cancer Center, Kansas City

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH